

**APPENDIX A - SPECIFICATION/CLAIM AMENDMENTS  
INCLUDING NOTATIONS TO INDICATE CHANGES MADE**

Serial No.: 09/727,739

Confirmation No.: 4181

Docket No.: 255.00040101

Amendments to the following are indicated by underlining what has been added and bracketing what has been deleted. Additionally, all amendments have been shaded.

**In the Claims**

For convenience, all pending claims are shown below:

1. An isolated or purified somatostatin polypeptide comprising a polypeptide selected from the group consisting of:
  - (a) a polypeptide comprising SEQ ID NO:15;
  - (b) a subunit of the polypeptide of (a) comprising SEQ ID NO:16 and at least 7 contiguous amino acids from SEQ ID NO:17;
  - (c) an analog of the polypeptide of (a) that has an amino acid sequence at least about 85% identical to SEQ ID NO:15; and
  - (d) an analog of the subunit of (b) having an amino acid sequence at least about 90% identical to the amino acid sequence of the subunit;wherein the somatostatin polypeptide binds to a somatostatin receptor.
2. The somatostatin polypeptide of claim 1, wherein the somatostatin polypeptide comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs:2, 16, 17, 18, and 19.
3. (Twice Amended) ~~[A]~~ An isolated or purified polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs:15, 17, ~~[18,]~~ and 19.
4. (Twice Amended) ~~[A]~~ An isolated or purified polynucleotide comprising at least one nucleotide sequence that encodes at least one somatostatin polypeptide of claim 1.
5. The polynucleotide of claim 4 comprising SEQ ID NO:20.

*Amendment and Response under 37 C.F.R. §1.116- Appendix A*

A-2

*Applicant(s): Sheridan et al.**Serial No.: 09/727,739**Confirmation No.: 4181**Filed: December 1, 2000**For: SOMATOSTATINS AND METHODS*

---

6. A polynucleotide that is substantially complementary to the polynucleotide of claim 4.
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. A fusion polypeptide comprising an N-terminal somatostatin region comprising at least one first amino acid sequence comprising a somatostatin polypeptide of claim 1 covalently linked to a C-terminal region comprising a second amino acid sequence.
13. The fusion polypeptide of claim 12 wherein the second amino acid sequence encodes a bioactive moiety.
14. The fusion polypeptide of claim 12 wherein the first amino acid sequence comprises at least one amino acid sequence selected from the group consisting of NOs: 15, 16, 17, 18, and 19.
15. The fusion polypeptide of claim 13 wherein the first amino acid sequence comprises SEQ ID NO:18.